Radiotherapy

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain patients with advanced head and neck squamous cell carcinoma, according to results of a randomized phase 3 study.

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 trial.

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel immunotherapy regimen for glioblastoma developed based on his own studies.

Most women with breast cancer who paused endocrine therapy to get pregnant did not restart treatment after having a child, according to results of a nearly 25-year retrospective study.

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical cancer, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Institutional peer review led to recommended changes in more than one-quarter of radiotherapy treatment plans, according to results of a systematic review and meta-analysis.

Men who experience acute adverse effects after radiation therapy for prostate cancer may be at higher risk for more serious long-term urinary and bowel complications, according to results of a meta-analysis published in Lancet Oncology.

Patients with nasopharyngeal carcinoma who received radiotherapy in the morning survived longer than those who underwent radiotherapy later in the day, according to study results.

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck.